Market Overview

UPDATE: Wedbush Securities Initiates Regulus Therapeutics at Outperform on Pipeline Progress

Analyst Highlights Regulus Therapeutics' 'Disruptive 2016 Catalysts'
Biotech Beat: Analysts Bullish on Celgene Corporation (CELG) and Regulus Therapeutics Inc (RGLS)

Wedbush Securities initiated coverage on Regulus Therapeutics (NASDAQ: RGLS) with an Outperform rating and a $10 price target.

Wedbush Securities noted, "Regulus is developing oligonucleotide drugs that target microRNA, important regulators of gene expression whose dysregulation is implicated in a variety of diseases and disease states. Oligonucleotide drug discovery and development is rapid and predictable as drugs are assembled using the complementary microRNA target as a template, and other oligonucleotide drugs inform ADME, pK, safety and tolerability."

Regulus Therapeutics closed at $4.34 on Wednesday.

Latest Ratings for RGLS

Apr 2016Chardan CapitalInitiates Coverage onBuy
Apr 2016BMO CapitalInitiates Coverage onOutperform
Dec 2015Wells FargoInitiates Coverage onOutperform

View More Analyst Ratings for RGLS
View the Latest Analyst Ratings

Posted-In: Wedbush SecuritiesAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (RGLS)

View Comments and Join the Discussion!